Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial

•Methylsulfonylmethane is used for pain treatment.•Taking Methylsulfonylmethane for 16 weeks does not change physiologic parameters.•Taking Methylsulfonylmethane for 16 weeks does not change hematologic markers.•Taking Methylsulfonylmethane for 16 weeks does not change liver or kidney functions. To...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Complementary therapies in medicine 2019-08, Vol.45, p.85-88
Hauptverfasser: Crawford, Paul, Crawford, Amanda, Nielson, Frederick, Lystrup, Robert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Methylsulfonylmethane is used for pain treatment.•Taking Methylsulfonylmethane for 16 weeks does not change physiologic parameters.•Taking Methylsulfonylmethane for 16 weeks does not change hematologic markers.•Taking Methylsulfonylmethane for 16 weeks does not change liver or kidney functions. To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain. We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, “The use of Methylsulfonylmethane (MSM) in the treatment of low back pain,” to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight. Family Medicine Residency, Mike O’Callaghan Military Medical Center. Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine. Analysis of outcome measures showed no significant difference between MSM and placebo (p 
ISSN:0965-2299
1873-6963
DOI:10.1016/j.ctim.2019.05.022